## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Machinaton	D C	20540	
Nashington,	D.C.	20549	

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Finizio Robert G				2. Issuer Name <b>and</b> Ticker or Trading Symbol TherapeuticsMD, Inc. [ TXMD ]						(Check	Relationship of Reporting Person(s) to Issuer (Check all applicable)					
										X	Director		10% Ow			
(Last) (First) (Middle)											X	Officer (g below)	ive title	Other (s below)	pecify	
951 YAMATO ROAD					3. Date of Earliest Transaction (Month/Day/Year) 03/30/2020							CEO				
SUITE 220				١	03/30/2020											
(Street) BOCA RA	ATON FL	ı	33431	4	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Indiv	, , ,					
(City)	(St	ate)	(Zip)	_	Form filed by More than One Reporting Person									ng Person		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			Saction 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a)			5. Amount Securities Beneficially Following Reported	For Owned (D)	m: Direct or Indirect Instr. 4)	. Nature of ndirect seneficial Dwnership					
								Code V	Amou	nt	(A) or (D)	Price	Transaction (Instr. 3 and			Instr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Code	saction Derivative				Underlying Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	n Title		Amount or Number of Shares	(Instr. 4)			
Performance Stock Units	\$0	03/30/2020		A		475,000 <sup>(1)</sup>		(1)	(1)		mmon tock	475,000(1)	\$0	475,000 <sup>(1)</sup>	D	
Restricted Stock Units	\$0	03/30/2020		A		475,000		(2)	(2)		mmon tock	475,000	\$0	475,000	D	

## **Explanation of Responses:**

- 1. The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.
- 2. Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.

/s/ Robert G. Finizio

04/01/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.